SEC Form SC 13G filed by Oruka Therapeutics Inc.

10/7/24 11:37:08 AM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $ORKA alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 ORUKA THERAPEUTICS COMMON STOCK Cusip #687604108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #687604108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,512,300 Item 6: 0 Item 7: 5,512,300 Item 8: 0 Item 9: 5,512,300 Item 11: 15.345% Item 12: HC Cusip #687604108 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 5,512,300 Item 8: 0 Item 9: 5,512,300 Item 11: 15.345% Item 12: IN Item 1(a). Name of Issuer: ORUKA THERAPEUTICS Item 1(b). Address of Issuer's Principal Executive Offices: 855 OAK GROVE AVE., SUITE 100 MENLO PARK, CA 94025 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 687604108 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 5,512,300 (b) Percent of Class: 15.345% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 5,512,300 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ORUKA THERAPEUTICS. No one other person's interest in the COMMON STOCK of ORUKA THERAPEUTICS is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. October 4, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on October 4, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ORUKA THERAPEUTICS at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $ORKA alert in real time by email

Recent Analyst Ratings for

$ORKA

Date	Price Target	Rating	Analyst
12/18/2025	$75.00	Overweight	Piper Sandler
11/13/2025	$45.00	Buy	Jefferies
10/27/2025	$60.00	Buy	Guggenheim
10/13/2025	$48.00	Overweight	Barclays
5/22/2025	$44.00	Buy	BTIG Research
2/4/2025	$20.00	Outperform	Wolfe Research
10/11/2024	$49.00	Buy	Stifel
10/7/2024	$45.00	Buy	H.C. Wainwright

More analyst ratings

SEC Form SC 13G filed by Oruka Therapeutics Inc.

10/7/24 11:37:08 AM ET

$ORKA

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $ORKA alert in real time by email

Recent Analyst Ratings for

$ORKA

Date	Price Target	Rating	Analyst
12/18/2025	$75.00	Overweight	Piper Sandler
11/13/2025	$45.00	Buy	Jefferies
10/27/2025	$60.00	Buy	Guggenheim
10/13/2025	$48.00	Overweight	Barclays
5/22/2025	$44.00	Buy	BTIG Research
2/4/2025	$20.00	Outperform	Wolfe Research
10/11/2024	$49.00	Buy	Stifel
10/7/2024	$45.00	Buy	H.C. Wainwright

More analyst ratings

SEC Form SC 13G filed by Oruka Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ORKA

SEC Form SC 13G filed by Oruka Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ORKA

$ORKA
SEC Filings

SEC Form SCHEDULE 13G filed by Oruka Therapeutics Inc.

SEC Form 144 filed by Oruka Therapeutics Inc.

Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

$ORKA
Insider Purchases

Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,407,368 worth of shares (122,882 units at $11.45) (SEC Form 4)

$ORKA
Insider Trading

Chief Medical Officer Goncalves Joana was granted 32,500 shares, increasing direct ownership by 2,141% to 34,018 units (SEC Form 4)

Chief Operating Officer Sandler Laura Lee was granted 32,500 shares, increasing direct ownership by 16% to 237,584 units (SEC Form 4)

SVP, Finance Agarwal Arjun was granted 17,500 shares, increasing direct ownership by 995% to 19,258 units (SEC Form 4)

$ORKA
Press Releases

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

$ORKA
Analyst Ratings

Piper Sandler initiated coverage on Oruka Therapeutics with a new price target

Jefferies initiated coverage on Oruka Therapeutics with a new price target

Guggenheim initiated coverage on Oruka Therapeutics with a new price target

$ORKA
Leadership Updates

Oruka Therapeutics Announces New Board Member and Board Transition

$ORKA
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Oruka Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

SEC Form SC 13G filed by Oruka Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ORKA

SEC Form SC 13G filed by Oruka Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ORKA

$ORKA SEC Filings

SEC Form SCHEDULE 13G filed by Oruka Therapeutics Inc.

SEC Form 144 filed by Oruka Therapeutics Inc.

Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

$ORKA Insider Purchases

Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,407,368 worth of shares (122,882 units at $11.45) (SEC Form 4)

$ORKA Insider Trading

Chief Medical Officer Goncalves Joana was granted 32,500 shares, increasing direct ownership by 2,141% to 34,018 units (SEC Form 4)

Chief Operating Officer Sandler Laura Lee was granted 32,500 shares, increasing direct ownership by 16% to 237,584 units (SEC Form 4)

SVP, Finance Agarwal Arjun was granted 17,500 shares, increasing direct ownership by 995% to 19,258 units (SEC Form 4)

$ORKA Press Releases

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

$ORKA Analyst Ratings

Piper Sandler initiated coverage on Oruka Therapeutics with a new price target

Jefferies initiated coverage on Oruka Therapeutics with a new price target

Guggenheim initiated coverage on Oruka Therapeutics with a new price target

$ORKA Leadership Updates

Oruka Therapeutics Announces New Board Member and Board Transition

$ORKA Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Oruka Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

Recent Analyst Ratings for
$ORKA

Recent Analyst Ratings for
$ORKA

$ORKA
SEC Filings

$ORKA
Insider Purchases

$ORKA
Insider Trading

$ORKA
Press Releases

$ORKA
Analyst Ratings

$ORKA
Leadership Updates

$ORKA
Large Ownership Changes